Liposome-encapsulated doxorubicin in metastatic breast cancer

被引：0
|
作者：
Boer R.D. [1 ]
机构：
[1] Austin and Repatriation Medical Centre, Melbourne
来源：
Breast Cancer Research | / 3卷 / 1期
关键词：
Cardiotoxicity; Doxorubicin; Liposome; Metastatic breast cancer;
D O I：
10.1186/bcr-2001-68447
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
相关论文
共 50 条
  • [1] Liposome-encapsulated doxorubicin plus cyclophosphamide as first line therapy in metastatic breast cancer
    Heras, Vasilios
    Hatzopoulos, Antonios
    Heras, Panagiotis
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 83 - 83
  • [2] PHARMACOKINETICS OF LIPOSOME-ENCAPSULATED DOXORUBICIN
    RAHMAN, A
    GUTIERREZ, P
    RASCHID, S
    MHATRE, RL
    SCHEIN, PS
    [J]. FEDERATION PROCEEDINGS, 1981, 40 (03) : 685 - 685
  • [3] Liposome-encapsulated doxorubicin plus cyclophosphamide as first-line therapy in metastatic breast cancer: A phase II study
    Latiano, T. P.
    D'Addetta, C.
    Tozzi, L.
    Cilenti, G.
    Piano, A.
    Valori, V. M.
    Bisceglia, M.
    Maiello, E.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : VII145 - VII145
  • [4] Liposome-encapsulated doxorubicin citrate in previously treated recurrent/metastatic gynecological malignancies
    Angioli, R.
    Palaia, I.
    Calcagno, M.
    Manci, N.
    Zullo, M. A.
    Bellati, F.
    Perniola, G.
    De Vivo, A.
    Panici, P. Benedetti
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (01) : 88 - 93
  • [5] Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
    Valero, V
    Buzdar, AU
    Theriault, RL
    Azarnia, N
    Fonseca, GA
    Willey, J
    Ewer, M
    Walters, RS
    Mackay, B
    Podoloff, D
    Booser, D
    Lee, LW
    Hortobagyi, GN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1425 - 1434
  • [6] CLINICAL-STUDIES OF LIPOSOME-ENCAPSULATED DOXORUBICIN
    GABIZON, A
    ISACSON, R
    LIBSON, E
    KAUFMAN, B
    UZIELY, B
    CATANE, R
    BENDOR, CG
    RABELLO, E
    CASS, Y
    PERETZ, T
    SULKES, A
    CHISIN, R
    BARENHOLZ, Y
    [J]. ACTA ONCOLOGICA, 1994, 33 (07) : 779 - 786
  • [7] Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
    Harris, L
    Batist, G
    Belt, R
    Rovira, D
    Navari, R
    Azarnia, N
    Welles, K
    Winer, E
    [J]. CANCER, 2002, 94 (01) : 25 - 36
  • [8] Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer
    Batist, G
    Ramakrishnan, G
    Rao, CS
    Chandrasekharan, A
    Gutheil, J
    Guthrie, T
    Shah, P
    Khojasteh, A
    Nair, MK
    Hoelzer, K
    Tkaczuk, K
    Park, YC
    Lee, LW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) : 1444 - 1454
  • [9] Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
    Shapiro, CL
    Ervin, T
    Welles, L
    Azarnia, N
    Keating, J
    Hayes, DF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1435 - 1441
  • [10] Randomized phase III trials of Myocet (liposome-encapsulated doxorubicin) vs. doxorubicin or epirubicin in first-line treatment of metastatic breast cancer.
    Batist, G
    Winer, E
    Chan, S
    Jain, D
    Lee, L
    Azarnia, N
    [J]. ANNALS OF ONCOLOGY, 2000, 11 : 26 - 26
12345